Stem cell therapies have come a long way since the cloning of Dolly the sheep in 1996, with discoveries such as CRISPR gene editing and induced pluripotent stem cells (iPSCs) offering new hope for treating a variety of diseases. However, the regulatory framework that governs these therapies has remained largely unchanged since the 1990s, failing to keep up with scientific advancements.
The FDA’s existing regulations, such as the 361 and 351 classifications, were established in a time when stem cell research was still in its infancy. These regulations are now outdated, as they don’t account for newer techniques such as CRISPR, which allows scientists to precisely edit genes, or iPSCs, which enable the conversion of ordinary cells into pluripotent stem cells.
As a result, modern stem cell treatments are caught in a regulatory framework that doesn’t adequately address the complexity of current research. For instance, CRISPR and iPSC-based therapies are often left in a gray area where the rules governing their approval don’t fully apply. The lack of clarity in these regulations holds back innovation and delays patient access to potentially life-saving treatments.
To move forward, the FDA needs to update its regulatory framework to match the advancements in stem cell science. With a more modern approach, patients would have access to cutting-edge therapies sooner, and researchers would have clearer guidelines to follow. Updating these laws will ensure that stem cell therapies can reach their full potential while maintaining patient safety.
Are you considering stem cell treatment or regenerative therapy? Don’t make a decision without being fully informed. Download our free expert-curated list of 20 critical questions will empower you to evaluate potential providers with confidence and help you decide on the best outcome for your health.
